Buy this article for $3.95

Have a coupon or promotional code? Enter it here:

When you buy this article you'll get access to the ePub version, a downloadable PDF, and the ability to print the full article.

Source:

Nursing2015

June 2004, Volume 34 Number 6 , p 30 - 30

Authors

Abstract

© 2004 Lippincott Williams & Wilkins, Inc. Volume 34(6)             June 2004             p 30 Statin under fire [DRUG NEWS: LIPID-LOWERING DRUG]

The consumer group Public Citizen has filed a petition with the FDA seeking to remove Crestor (rosuvastatin) from the market because of dangerous adverse reactions. Crestor, a lipid-lowering drug, was first marketed in the United States in September 2003. Since then, seven patients developed rhabdomyolysis, a potentially fatal condition involving the breakdown of muscle tissue, and nine experienced kidney failure or damage. One woman died from rhabdomyolysis and kidney damage.

Rhabdomyolysis is a potential complication of all statin drugs. In 2001, the FDA removed another statin, Baycol, from the market because of several deaths from rhabdomyolysis worldwide.

Crestor won FDA approval despite concerns about its potential to cause rhabdomyolysis, ...

To continue reading, buy this article for just $3.95.

Have a coupon or promotional code? Enter it here: